Team members for the OmniaBio
Neil Blackburn earned his PhD from the University of Guelph, where he focused on protein biochemistry and immunology. His post-doctoral training at Eli Lilly and Company focused on dendritic cell tolerization and the interaction of immune cells with novel TLR ligands. Neil next led the development and commercialization of immunochemical-based clinical assays and companion medical devices […]
Neil Blackburn, Ph.D. Read More »
For over 20 years, Dr. Jessica Tate has been at the forefront of viral vector research, pioneering groundbreaking advancements in the gene therapy industry. With a Ph.D. in molecular genetics from the University at Buffalo, she has leveraged her extensive expertise to facilitate the progression of more than 70 viral vector products, four of which
Jessica Tate, Ph.D. Read More »
Ken Harris has dedicated over three decades to revolutionizing health care. With a profound expertise spanning 35 years in the field, Ken has been at the forefront of innovation and leadership in technology, medical devices and therapeutics. In his most recent role, Ken spearheaded the academic medicine and public health vertical within Amazon’s $90 billion
Tony is an Executive leader with 46 years of pharmaceutical manufacturing expertise that covers building facilities, optimizing operations, and supporting therapeutics developers from clinical to commercial scale. With deep experience in all facets of operations, revenue growth, and quality assurance,Tony has developed a strong track record in ensuring company and client success, with proven turnaround
Michael Israels is the Chief Financial Officer of CCRM. Prior to joining CCRM, Michael was a Management Consultant at Ernst & Young LLP, President of BEST Funds, a venture capital company, and CEO of Convexus Managed Services Inc., a start-up fund administration company. As CFO, Michael is responsible for overseeing operational effectiveness and efficiency at
Sherif is a CIO who led major transformation initiatives in multiple industries. His experience spans over 35 years in the Information Technology (IT) and business operations space. He exhibits deep knowledge of business solutions and applications, IT enterprise infrastructure, project/program management and business relationship management. He has extensive history in the software development, automotive, manufacturing
Mitch Sivilotti is a respected leader in the Life Sciences industry and serves as the President and Chief Executive Officer of OmniaBio Inc., a CDMO serving the cell and gene therapy market. Most recently, Mitch was the Chief Operating Officer at CCRM, a Toronto-based cell and gene therapy (CGT) accelerator focused on cell therapy and
